Eli Lilly stock weekly forecast: rebound odds rise as Stochastic RSI enters oversold zone

Traders Union
All News
Stocks
Eli Lilly rises 1.77% this week

Highlights

Shares of Eli Lilly rose 1.77% over the past week to $1,156, trading in a narrow range with mixed momentum signals.
The stock is currently below its 50-day moving average, indicating limited conviction for a sustained trend either higher or lower.
Forecast expects shares to consolidate between $1,151 and $1,162, with an overall range of $1,118 to $1,189 and a greater probability of decline.

Earnings surge and drug approvals boost sentiment as LLY raises outlook

LLY posted strong second-quarter 2026 results, with non-GAAP earnings per share reaching $8.38 and revenue surging 47.7% to $22.97 billion, according to AlphaStreet and Pluang. This performance was driven by high sales of Mounjaro and Zepbound, which also supported several acquisitions throughout the quarter. The FDA granted first-line approval to Jaypirca for untreated chronic lymphocytic leukemia, adding to positive momentum as LLY advanced its obesity pipeline and raised full-year sales guidance.

Limited conviction as mixed momentum and narrow range shape weekly signals

On the daily chart, the move has been defined by a contained move within a narrow range, with seven-day volatility at 6.62%. Momentum signals are mixed, as the MACD maintains a sell stance while the Stochastic RSI is now in the oversold zone at 6.03, signalling potential for a near-term rebound. Immediate support stands at $1,151, while resistance comes in at $1,162, defined by the Ichimoku Kijun. The overall setup points to limited directional conviction despite the recent price uptick.

Consolidation expected with breakout risks defined by key support and resistance

Over the coming trading week, the forecast expects the stock to trade within a $1,118 to $1,189 range, with probabilities skewed 33% for an increase and 67% for a decrease. The base case sees consolidation between $1,151 and $1,162. A sustainable move above $1,162 would suggest a stronger recovery. Failure to hold above $1,151 opens the door to weakness toward the lower end of the expected range.

Sholanke Dele, Market Strategist, sees Eli Lilly shares caught in a cautious standoff this week. Despite strong Q2 results and positive drug news boosting sentiment, technical conviction remains lacking, with the daily chart showing narrow movement and mixed momentum indicators. Resistance at $1,162 is holding, while support at $1,151 looks fragile as probabilities still favor weakness. Dele believes the base case is for consolidation within the $1,151–$1,162 range, and warns that a break below $1,151 could trigger a push toward $1,118 in the days ahead. "As long as shares remain capped by $1,162, I stay defensive and see limited upside for now."

Previously it was reported that Eli Lilly's mixed results from its obesity drug pipeline and broader sector catalysts had led to cautious stock advances despite macro uncertainty. The current technical setup introduces a new risk dimension, with a narrow trading range signaling that a decisive break above $1,162 could trigger a more directional move in the near term.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.